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A B S T R A C T
Impaired bone regeneration by excess inﬂammation leads to failure of bone healing. Current therapies display
limited beneﬁts making new treatments imperative. Our recent discoveries of the anti-inﬂammatory char-
acteristics of bromodomain and extra terminal domain (BET) inhibitors, N-methylpyrrolidone (NMP) and N,N-
Dimethylacetamide (DMA), implicate possible therapeutic use of epigenetic drugs in inﬂammation-impaired
bone healing.
Here, we investigated the eﬀects of NMP and DMA on osteogenesis in vitro and ex vivo under the inﬂuence of
TNFα, a key cytokine responsible for impaired fracture healing. NMP and DMA pre-treatment recovered TNFα-
inhibited expression of essential osteoblastic genes, Alp, Runx2, and Osterix as well as mineralization in mul-
tipotent stem cells, but not in pre-osteoblasts and calvarial osteoblasts. The mechanism of action involves the
recovery of TNFα-suppressed BMP-induced Smad signaling and the reduction of TNFα-triggered ERK pathway.
In addition, ERK inhibitor treatment diminished the eﬀect of TNFα on osteogenesis, which reinforces the role of
ERK pathway in the adverse eﬀect of TNFα. Furthermore, endochondral ossiﬁcation was analyzed in an ex vivo
bone culture model. TNFα largely abrogated BMP-promoted growth of mineralized bone while pre-treatment of
NMP and DMA prevented the deleterious eﬀect of TNFα. Taken together, these data shed light on developing
low- aﬃnity epigenetic drugs as new therapies for inﬂammation-compromised bone healing.
1. Introduction
Bone fractures are the most common and costly traumatic injuries
worldwide. In the US, there are approximately 15 million fracture cases
annually with the healthcare expenditures of more than 60 billion
dollars. Bone fractures thus pose a substantial socioeconomic burden
[1] on top of the dramatic reduction in life quality of the patients.
A bone fracture occurs when the force applied on bone exceeds its
strength, leading to a break, subsequently reducing the mechanical
stability of the bone. Although the skeletal system features extra-
ordinary regenerative capacity to repair fractures, about 10% of frac-
tures fail to heal normally [2]. Failure of the fracture healing is due to
impaired bone regeneration process that causes an increased risk of
developing deleterious complications, such as non-unions [3].
Bone regeneration during fracture healing is a well-orchestrated
physiological process, and many factors can interfere with it. However,
excess inﬂammation triggered by additional injuries or comorbid
diseases is described as the most common cause [4]. Unlike controlled
inﬂammation which is required for normal fracture healing, excess
inﬂammatory responses create a systemic increased expression of sev-
eral pro-inﬂammatory cytokines [3] among which tumor necrosis
factor-α (TNFα) is a critical cytokine associated with impaired new
bone formation [5]. Several studies have shown that high level of TNFα
inhibits the expression of various osteogenic genes, thus blocking os-
teogenic diﬀerentiation of mesenchymal stem cells (MSCs) and the
maturation of osteoprogenitors [6–14]. Hence, anti-TNFα therapeutics
have been developed to treat inﬂammation-impaired bone regenera-
tion. However, current anti-TNFα agents show unsatisfactory clinical
beneﬁts so far [15]. Thus, eﬀective therapies to ﬁne-tune the patholo-
gical action of TNFα are still lacking. For that, an emerging class of
therapeutics, called epigenetic drugs, oﬀers alternative treatment op-
tions to explore.
Epigenetics refers to the heritable modiﬁcations that control gene
expression without altering the genetic sequence in the genome [16].
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Common epigenetic modiﬁcations involve DNA methylation, histone
modiﬁcation (i.e., acetylation and methylation), and non-coding RNA
(i.e., lncRNA). Bromodomains are “readers” that bind acetylated lysines
in histone tails, and their most important function is the regulation of
gene transcription by the recruitment of diﬀerent molecular partners.
Thus, proteins containing bromodomains are considered as epigenetic
regulators. Since the activity of epigenetic factors is likely to be che-
mically modulated, they are ideal targets for controlling gene expres-
sion and for modulating their activity. These characteristics oﬀer con-
siderable potential for the development of new drugs [17]. Recent
report of the clinical applicability of a BET inhibitor, (+)-JQ1 in
treating osteoporosis revealed that BET inhibitors might be promising
therapeutics for inﬂammation-related bone disorders. [18].
Recently, two FDA-approved drug excipients, N-methylpyrrolidone
(NMP) and N,N-Dimethylacetamide (DMA) were discovered to act as
BET bromodomain inhibitors [19–21]. Notably, studies have demon-
strated that both NMP and DMA reduce inﬂammation and favorably
inﬂuence bone remodeling in vivo by suppressing osteoclastogenesis
and promoting the anabolic eﬀect of BMP2 [19,20,22,23]. Taken to-
gether, these results suggest that they are candidates for developing
eﬀective treatments for inﬂammation-impaired bone healing. However,
the data regarding the eﬀects of NMP and MDA on osteoblast diﬀer-
entiation under excess inﬂammation is lacking.
To that end, we investigated the ability of NMP and DMA to
counteract the deleterious eﬀect of TNFα on osteogenesis in vitro and on
metatarsal bone growth ex vivo, a widely used model to study new bone
formation.
2. Materials and methods
2.1. Reagents and antibodies
Dulbecco's modiﬁed eagle medium (DMEM) with GlutaMAX sup-
plement, minimum essential medium eagle-alpha (MEM-α), fetal bo-
vine serum (FBS), L-glutamine, penicillin, amphotericin B, strepto-
mycin, protease and phosphatase inhibitors cocktail, NE-PER nuclear/
cytoplasmic extraction reagents, and collagenase were obtained from
Thermo Fisher Scientiﬁc (Waltham, Ma, USA). Primers for RT-PCR
(QuantiTect primer assay) and RNA extraction kit (RNeasy kit) were
purchased from Qiagen (Hilden, Germany). iScript reverse transcription
supermix, SsoAdvanced universal SYBR green supermix, and Bradford
protein assay reagent were obtained from Bio-Rad Laboratories
(Hercules, CA, USA) The BCA kit for protein determination was from
Pierce. Anti-RUNX2 (D1L7F), anti-pSmad1/5/9 (D5B10), anti-p-NK-ĸB
p65 (93H1), anti-NK-ĸB p65 (D14E12), anti-pp44/42 MAPK
(D13.14.4E), anti-p44/42 MAPK (137F5), anti-pp38 (D3F9), anti-p38
MAPK (D13E1), anti-pSAPK/JNK (81E11), anti-GAPDH (D16H11),
anti-TBP (D5C9H), and anti-rabbit-IgG HRP-linked antibodies were
purchased from Cell Signaling Technology (CST, Inc., USA). Anti-Sp7
(ab22552), anti-Smad1/5/9 (ab66737), and anti-SAPK/JNK
(ab208035) were from Abcam (Cambridge, UK). All other chemicals
were from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Cell cultures
Both C2C12 and MC3T3-E1 cell line was purchased from American
Type Culture Collection (ATCC). C2C12 and MC3T3-E1 were cultured
in DMEM+GlutaMAX-I and MEM-α medium without ascorbic acid,
respectively. All culture media were supplemented with 10% FBS and
antibiotics (100 units/ml penicillin and 100 units/ml streptomycin).
Cells were incubated at 37 °C with 5% CO2 in humidiﬁed air. The os-
teogenic medium for MC3T3-E1 consisted of MEM-α supplemented
with 50 μg/ml L-ascorbic acid and 10mM β-glycerol phosphate. Bone-
marrow derived stem cells (BM-MSCs) were isolated from long bone of
6-week-old Sprague Dawley female rats as described previously [24],
and were then maintained in DMEM+GlutaMAX-I medium. Rat
calverial osteoblasts (rOBs) were isolated as described in [25] and
further cultured in DMEM. For osteogenesis, medium was supple-
mented with 50 μg/ml ascorbic acid, 2 mM β-glycerol phosphate, and
10 nM dexamethasone.
2.3. Alkaline phosphatase (ALP) activity assay and staining
The protocol was previously described in [21]. In short, cells were
seeded at a density of 5×104 cells/cm2 in 6- or 24-well plates (n=3
per group) for 16–24 h before incubation with indicated molecules.
After at least six days of incubation, cells were washed with PBS and
then scraped in 0.56M 2-amino-2-methyl-1-propanol. After homo-
genization and subsequent centrifugation, the supernatants were col-
lected and tested for ALP activity using p-nitrophenyl phosphate as a
substrate. The protein content of the lysates was determined using
Bradford protein assay reagent for normalization purpose. To examine
alkaline phosphatase activity histochemically, cells were ﬁxed for
10min with 10% Formalin (1ml per well in 6-well plates) at room
temperature. After washing with PBS, cells were stained as in [19].
Photos of the stained cells were taken using CCD camera.
2.4. Quantitative real-time RT-PCR
RNA was extracted using the RNeasy mini kit (Qiagen) and then
reverse transcribed into cDNA using iScript reverse transcription su-
permix for qRT-PCR (Bio-Rad). The resulting cDNA was subjected to
real-time PCR with gene-speciﬁc primers (QuantiTect primer assay,
Qiagen, see Table 1 for details) using SsoAdvanced universal SYBR
green supermix and the CFX Connect real-time system (Both were from
Bio-Rad).
2.5. Western blot analysis
Total cell lysates were extracted using RIPA buﬀer supplemented
with protease and phosphatase inhibitors cocktail and subjected to
analysis as previously described [19]. For speciﬁc experiments, nuclear
cell extracts were isolated using NE-PER nuclear and cytoplasmic ex-
traction reagents. An equal amount of proteins was separated on a
4–20% precast polyacrylamide gel and transferred to a PVDF mem-
brane using the precast Trans-Blot turbo stack (All were from Bio-Rad).
Proteins were detected by appropriate primary antibodies and HRP-
linked secondary antibody. The signals of proteins were detected using
Clarity Western ECL substrate and ChemiDoc MP imaging system (Both
were from Bio-Rad).
2.6. Alizarin red staining
Cell were washed with PBS and ﬁxed using 70% ethanol for 1 h.
Next, cells were stained with Alizarin red solution as described in [21].
The stained cells were then photographed.
2.7. Immunoﬂuorescence (IF) staining
Cells were seeded on 12-well chamber slides (Ibidi, Planegg,
Germany) 24 h before stimulation. Cells were then stimulated with in-
dicated molecules for speciﬁed time and ﬁxed with 4% formaldehyde.
Table 1
Primers for qPCR.
Gene Species Company Catalog nr.
Sp7_Osterix Mouse Qiagen QT00293181
Runx2 Mouse Qiagen QT00102193
Alp Mouse Qiagen QT00157717
Gapdh Mouse Qiagen QT01658692
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Specimens were rinsed with PBS, followed by blocking with blocking
buﬀer (1× PBS/5% normal serum/0.3% Triton™ X-100) for 60min.
Samples were incubated with anti-NK-ĸB p65 antibody (1:400) diluted
in antibody dilution buﬀer (1× PBS/1% BSA/0.3% Triton™ X-100) for
24 h at 4 °C, followed by incubation with anti-rabbit IgG (H+L), F(ab′)
2 Fragment (Alexa Fluor® 488 Conjugate) for 1–2 h. Afterward, the
samples were incubated with DyLight™ 554 Phalloidin for 20min and
then with Prolong® Gold Antifade Reagent with DAPI (CST). Lastly,
slides were cured in the dark for overnight at room temperature before
imaging with ZOE™ Fluorescent cell imager (Bio-Rad).
2.8. Metatarsal bone culture
The model was adopted from [26]. Brieﬂy, metatarsal bones from
hind limbs of Sprague Dawley pups (post-natal day one, PN1) from the
same litter were isolated. All the metatarsals, except the ﬁrst and ﬁfth
ones, were carefully dissected and transferred into the wells on 24-well
plates with 200 μl/well of MEM-α medium without ribonucleosides and
supplemented with 0.2% BSA (Sigma-Aldrich), 5 μg/ml L-ascorbic acid
2 phosphate, 1 mM β-glycerol phosphate, 100 units/ml Penicillin and
Streptomycin, and 1.25 μg/ml fungizone. Metatarsals were then sti-
mulated with indicated molecules for 14 days. Medium was changed
every 3 days throughout the culture period. To assess endochondral
ossiﬁcation of metatarsals, images were taken with CCD camera on the
ﬁrst day and the last day of the culture period, followed by the calcu-
lation of changes in mineralized length using ImageJ Software (NIH,
USA).
2.9. Statistical analysis
All statistical analyses were performed with GraphPad Prism 7.
Results from in vitro or ex vivo studies were expressed as the
mean ± SD and were compared by Student's t-test or ANOVA, re-
spectively. All results were considered signiﬁcantly diﬀerent for
p < 0.05.
Key resources table
Resource Source Identiﬁer
Antibodies
Anti-pSmad1/5/(D5B10) Cell Signaling
Technology
#13820
Anti-GAPDH Cell Signaling
Technology
#5174
Anti-p44/42 MAPK (137F5) Cell Signaling
Technology
#4695
Anti-pNFkB 65 Cell Signaling
Technology
#3033
Anti-pp38 (D3F9) Cell Signaling
Technology
#4511
Anti-pSAPK Cell Signaling
Technology
#4668
Anti-rabbit-IgG HRP-linked Cell Signaling
Technology
#7074
Anti-RUNX2 Cell Signaling
Technology
#12556
Anti-SAPK/JNK Abcam ab208035
Anti-Smad1/5/9 Abcam ab66737
ANTI-Sp7 Abcam ab22552
Anti-TBP Cell Signaling
Technology
#44059
CellLine
MC3T3-E1 ATCC CRL-2595
Chemical
2-Amino-2-methyl-1-propanol Sigma
Alizarin red Sigma
Amphotericin B Thermo Fisher Scientiﬁc
Dexamethasone Sigma
Formaldehyde Sigma
Formalin Sigma
Fungizone Thermo Fisher Scientiﬁc
GlutaMAX-I Thermo Fisher Scientiﬁc
L-glutamine Thermo Fisher Scientiﬁc
L-Ascorbic acid 2 phosphate Sigma
Penicillin Thermo Fisher Scientiﬁc
p-Nitrophenyl phosphate Sigma
Prolong® Gold Antifade Reagent with
DAPI
Cell Signaling
Technology
#8961
β-Glycerol phosphate Sigma
Streptomycin Thermo Fisher Scientiﬁc
X-100 Sigma
ProteinPeptide
CFX Bio-rad
Collagenase Thermo Fisher Scientiﬁc
3. Results
3.1. Eﬀects of NMP and DMA on TNFα-inhibited osteogenesis
To investigate the therapeutic eﬀects of NMP and DMA against in-
ﬂammation-repressed osteogenesis, we ﬁrst examined their abilities to
restore the expression of the early osteogenic marker, alkaline phos-
phatase (ALP), in C2C12 in the presence of TNFα. As mentioned in the
introduction, TNFα has been linked to direct suppression of osteogenic
diﬀerentiation and therefore used to mimic excess inﬂammation in our
study. In C2C12 cells, NMP and DMA pretreatment signiﬁcantly re-
versed the inhibitory eﬀect of TNFα on Alp mRNA expression (Fig. 1A).
Furthermore, staining and enzymatic activity of ALP were fully restored
from TNFα suppression with the presence of NMP or DMA (Fig. 1B). In
contrast, neither NMP nor DMA recovered TNFα-suppressed ALP ac-
tivities (Fig. 1C) and mineralization (Supplemental Fig. 1A) in pre-os-
teoblastic MC3T3-E1 cells and primary rat calvarial osteoblasts
(Fig. 1D). These results suggest that NMP and DMA are eﬀective on
TNFα-inhibited osteogenesis in cells before committing to the osteo-
genic lineage. Indeed, the data in C2C12 cells at diverse diﬀerentiation
stages conﬁrm that the counteractive eﬀect of NMP against TNFα is
largely diminished in cells that were already diﬀerentiated by BMP2
(Supplemental Fig. 1B and C). This observation supports the notion that
cells before lineage speciﬁcation are more sensitive to the pre-treatment
of NMP and DMA.
Next, we assessed the eﬀects of NMP and DMA on the expressions of
both early and late osteoblast-speciﬁc transcription factors, Runx2 and
Osx (Osterix). Both transcription factors are essential trans-activators,
which drive various vital osteogenic-speciﬁc genes during osteogenesis
and osteoblast maturation [27,28]. As shown in Fig. 2A, NMP and DMA
pretreatment reversed TNFα-reduced Runx2 mRNA level and restored
RUNX2 protein to a similar degree as in the rhBMP2 only-treated group
(Fig. 2C). Osx, on the other hand, was partially restored by the pre-
treatment of NMP or DMA at both mRNA (Fig. 2B) and protein levels
(Fig. 2D). Thus, NMP and DMA rescued the TNFα-induced impairments
of osteogenesis by restoring the expression of Runx2 and Osx.
Since NMP and DMA are bromodomain inhibitors [19,20], we as-
sumed that other bromodomain inhibitors might possess the same
therapeutic characteristics. To that end, we decided to test another
well-studied bromodomain inhibitor, JQ1. However, the data clearly
shows that neither 0.1 μM nor 1 μM of JQ1 countered TNFα-suppression
on osteogenesis (Supplemental Fig. 2). Taken together, we concluded
that the therapeutic eﬀects of bromodomain inhibitors in the context of
TNFα suppression are NMP- and DMA-speciﬁc, and unrelated to their
bromodomain binding aﬃnity.
3.2. Eﬀects of NMP and DMA on TNFα-impaired osteogenesis in primary
mesenchymal stem cells
Next, we intended to study the therapeutic eﬀects of NMP and DMA
on rat primary bone marrow-derived mesenchymal stem cells (BM-
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MSCs). Evidence has suggested that BM-MSCs are multipotent stem
cells that diﬀerentiate into osteoblasts under the appropriate environ-
mental cues [29]. Importantly, they are the primary source of re-
plenishing osteo-progenitors during new bone formation needed to re-
pair injured bone in vivo [29]. Hence, the study on MSCs could provide
additional information to better predict the eﬃcacy of NMP and DMA in
vivo. As shown in Fig. 3A, NMP and DMA could protect MSCs against
TNFα impaired osteogenesis based on the partial restoration of ALP
activity. Besides, the data suggest that the eﬀects of NMP and DMA are
BMP2-dependent. Consistent with our ﬁnding in cell lines, studies de-
monstrate that NMP and DMA could rescue TNFα-suppressed miner-
alization only when the MSCs were at the early stage of osteogenesis
(Fig. 3B), possibly during lineage commitment. Supporting evidence is
shown in Supplemental Fig. 3 that after passing the early diﬀerentiation
stage, the beneﬁcial eﬀects of pre-treating NMP and DMA were di-
minished whereas the deleterious eﬀect of TNFα persisted.
3.3. Mode of action of NMP and DMA
To dissect the mechanisms by which NMP and DMA curtail the in-
hibitory eﬀect of TNFα on osteogenesis, we examined several signaling
pathways associated with BMP2 and TNFα during osteoblast diﬀer-
entiation. Firstly, key signaling driving osteogenesis [30], Smad1/5/9,
was investigated (Fig. 4A). The analysis of the phosphorylation level of
Smad1/5/9 shows that TNFα signiﬁcantly reduced the amount of
BMP2-phosphorylated Smad1/5/9, whereas the addition of NMP and
DMA could fully restore the level of Smad phosphorylation. Therefore,
NMP and DMA counteract the eﬀect of TNFα by recovering TNFα-
suppressed activation of Smad pathway.
TNFα mainly activates NF-ĸB pathway to facilitate bone resorption
via promoting osteoclasts diﬀerentiation and to reduce new bone for-
mation via suppressing osteoblast diﬀerentiation. Eventually, the in-
creasing osteoclast-to-osteoblast ratio results in compromised bone re-
generation [14,31,32]. Previous studies demonstrated that both NMP
and DMA inhibit LPS-induced inﬂammatory responses in macrophages
Fig. 1. NMP and DMA restored TNFα-inhibited osteogenesis in multipotent stem cells (C2C12), but not in pre-osteoblasts (MC3T3-E1) or rat primary calvarial
osteoblasts (rOBs). Cells were pre-treated with NMP or DMA, followed by stimulation of indicated concentration of TNF-α and rhBMP2. (A) mRNA expression levels
of early marker, Alp, were measured by qRT-PCR and (B) ALP activity was measured by ALP enzymatic activity assay as well as ALP staining, respectively, after at
least 6 days in C2C12. (C) ALP activity was measured after 7 days using ALP enzymatic activity assay in MC3T3-E1. (D) ALP activity was measured after 7 days using
ALP enzymatic activity assay in rOBs. OM: Osteogenic medium. Error bar indicates S.D. from triplicate samples. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****:
p < 0.0001.
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by partially suppressing NF-ĸB pathway [19,23]. Therefore, we in-
vestigated the eﬀects of NMP and DMA on TNFα-activated NF-ĸB
pathway in C2C12. The analysis on phosphorylated p65, a transcription
regulator tightly linked to the activation of NF-ĸB pathway, demon-
strates that TNFα triggered the phosphorylation of p65. However, pre-
treatment with NMP or DMA did not interfere with TNFα-induced
phosphorylation of p65 (Fig. 4B). In accordance with this result, the
nuclear translocation of p65 also shows that NMP and DMA did not
aﬀect TNFα-induced p65 nuclear translocation (Supplemental Fig. 4).
The data suggest that the eﬀects of NMP and DMA on TNFα suppression
in multipotent cells is NF-ĸB-independent.
Next, we decided to examine mitogen-activated protein kinases
(MAPKs) pathways, including ERK1/2, JNK1/2, and p38, which are
known to modulate BMP2-induced osteogenesis [33–35]. Furthermore,
MAPKs pathways have been linked to the inhibitory eﬀect of TNFα on
osteoblastic diﬀerentiation [8]. Here, we revealed that TNFα activated
ERK pathway during BMP2-induced osteogenesis, particularly the
phosphorylation of ERK2. NMP and DMA pretreatment suppressed the
TNFα-triggered phosphorylation to its basal level (Fig. 5A). To conﬁrm
our ﬁnding, we used ERK inhibitor, U0126, to mimic the eﬀects of NMP
and DMA via direct suppression of TNFα-induced ERK activation.
Consistent with the result shown in Fig. 5A, we found that pre-treat-
ment with ERK inhibitor dose-dependently recovered TNFα-reduced
ALP activities (Fig. 5B). This data indicate that TNFα-activated ERK
pathway directly correlates to the suppressive eﬀects on osteogenesis.
In contrast, there were no clear diﬀerences in the phosphorylation le-
vels for JNK (Supplemental Fig. 5A) and p38 (Supplemental Fig. 5B)
between rhBMP2+TNFα group and NMP or DMA pre-treated group.
Hence, the data suggest that TNFα-inhibited osteogenesis is ERK-de-
pendent.
3.4. Eﬀects of NMP and DMA on TNFα-compromised new bone formation
ex vivo
To validate the therapeutic eﬀects of NMP and DMA in a system
under physiological-like condition, we decided to test their eﬃcacy in
an ex vivo metatarsal bone culture (Fig. 6A). This model has been
widely used to study the eﬀects of bioactive molecules on linear bone
growth and endochondral ossiﬁcation [26]. Fig. 6B demonstrates that
TNFα alone led to de-mineralization of metatarsal bone while rhBMP2
largely facilitated endochondral ossiﬁcation, as evidenced by a sig-
niﬁcant increase in the mineralized length. Noticeably, the addition of
TNFα in rhBMP2-treated bones resulted in complete suppression of
endochondral ossiﬁcation, while pre-treatment of NMP and DMA re-
covered the mineralization again. This result is consistent with our in
vitro ﬁndings and provides compelling evidence indicating the ther-
apeutic eﬀects of NMP and DMA on the level of an ex vivo model
system.
4. Discussion
Appropriate bone healing after fractures poses a great challenge in
clinical practice. Despite the advances in fracture treatments, some is-
sues that could interfere with the healing process remain unsolved,
particularly excess inﬂammation. Excess inﬂammation caused by
polytrauma or extensive tissue damages together with fractures have
been shown to impair bone regeneration severely [4]. Current treat-
ments simply antagonizing critical pro-inﬂammatory cytokines, such as
TNFα [15], were reported to show minor eﬃcacy. However, recent
discoveries of epigenetic drugs on the treatment of inﬂammation-as-
sociated bone disorders mark the dawn of the development of new
Fig. 2. NMP and DMA recovered TNFα-suppressed expression of crucial osteoblast-speciﬁc transcription factors, Runx2 and Osterix, in C2C12. Cells were pre-treated
with NMP or DMA, followed by stimulation of indicated concentration of TNF-α and rhBMP2. (A and C) Runx2 mRNA and nuclear protein levels were assessed after
72 h of stimulation by qRT-PCR and western blot, respectively. TBP (TATA-binding protein) served as a nuclear marker. (B and D) Osterix mRNA and protein levels
were analyzed after 120 h of stimulation. TBP and GAPDH were loading control. Error bar indicates S.D. from triplicate samples. *: p < 0.05; **: p < 0.01.
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therapy [18].
Recently, we showed that two FDA-approved small molecules, N-
methylpyrrolidone (NMP) and N,N-Dimethylacetamide (DMA), are low-
aﬃnity, broadband BET bromodomain inhibitors [19,36]. Both NMP
and DMA can inhibit inﬂammatory responses and osteoclast diﬀer-
entiation to attenuate bone resorption [19,22,23]. However, little is
known about the eﬀects of these BET inhibitors on osteoblast diﬀer-
entiation under inﬂammation. Here in this study, we found that NMP
and DMA rescued the expression of Alp, Runx2, Osx at both mRNA and
protein levels, thereby countering TNFα inhibition on osteogenesis in
multipotent stem cells. Consistent with the data from cell lines, ALP
activity and mineralization of MSCs were recovered by pre-treatment of
NMP and DMA.
In contrast, pre-osteoblasts and primary osteoblasts did not respond
to the pre-treatment of the inhibitors. These results suggest that the
beneﬁcial eﬀects of NMP and DMA against TNFα are sensitive to the
diﬀerentiation stages of cells. Thus, the time of the administration of
NMP and DMA is critical during bone healing. The initial inﬂammatory
phase during bone healing occurs from day 0 to day 3 when immune
cells remove necrotic tissues and trigger angiogenesis to initiate repair.
Afterward, the recruitment of MSCs and osteo-progenitors follows [2].
Since NMP and DMA are eﬃcacious on the cells before lineage
Fig. 3. Pre-treatment of NMP/DMA during lineage commitment could protect BM-MSCs against TNFα-suppressed osteogenesis. BM-MSCs were isolated from the
femurs of male wild-type Sprague Dawley (SD) rats. (A) Cells were pre-treated with NMP or DMA, followed by stimulation of indicated concentration of TNF-α and
rhBMP2 for 7 days. ALP activity was then measured using ALP enzymatic activity assay. (B) Cells were pre-treated with NMP or DMA, followed by stimulation of
indicated concentration of TNF-α and rhBMP2 for the ﬁrst 3 days, and then continued to diﬀerentiate with osteogenic supplements for 18 days. Culture medium was
renewed every 3 days. After 21 days, calcium deposition was assessed via Alizarin red staining. Error bar indicates S.D. from triplicate samples. *: p < 0.05; **:
p < 0.01.
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commitment, BET inhibitors should be applied locally at the healing
site between day 2 and day 3. In this way, the controlled inﬂammation
required for normal healing process will not be inhibited and the re-
cruited multipotent stem cells will immediately encounter the BET in-
hibitors before osteogenic diﬀerentiation.
JQ1 is the most studied BET inhibitor that shows anti-inﬂammatory
and anti-osteoclastogenic eﬀects both in vitro and in vivo [37]. For the
inﬂammation-compromised bone regeneration, JQ1 seems to be not
suitable since it suppresses osteoblast diﬀerentiation and bone forma-
tion. The eﬀect of JQ1 on osteoblast diﬀerentiation is probably due to
its high aﬃnity (nM range) compared to NMP and DMA (mM range).
Moreover, JQ1 is not able to reverse the detrimental eﬀect of TNFα on
osteogenesis. Taken together, our data show that low-aﬃnity broad-
band bromodomain inhibitors, like NMP and DMA, which have addi-
tional activities like to enhance osteogenesis by increasing the phos-
phorylation activity of BMP-receptors for Smad [21] appear to have
greater potential than JQ1 to improve bone regeneration in compro-
mised situations.
Runx2 and Osx are transcription factors that drive the diﬀerentia-
tion and maturation of osteoblasts. TNFα is described to down-regulate
the expression of Runx2 and Osx, thus inhibiting osteoblast diﬀer-
entiation [7,8,12,38–40]. Our data demonstrate that NMP and DMA are
able to recover TNFα-inhibited expression of Runx2 and Osx. For TNFα-
inhibited Runx2 expression, our data shows that NMP and DMA fully
recovered its protein level with a minor change in mRNA. One ex-
planation for this discrepancy is that NMP and DMA might restore
Runx2 expression by reducing its Smurf-mediated proteasome de-
gradation. Both Smurf1 and Smurf2 are well-known E3 ubiquitin ligases
responsible for ubiquitin/proteasome degradation of Runx2 during os-
teoblast diﬀerentiation [41,42]. To date, several pieces of evidence
have suggested that TNFα inhibits osteogenesis via up-regulating
Smurf1 and Smurf2, thereby promoting Smurf-mediated degradation of
Runx2 [43,44]. Therefore, we reasoned that NMP and DMA are likely to
suppress TNFα-driven Smurf1/2 expression, thus increasing the stabi-
lity of Runx2 to protect MSCs from the deleterious eﬀects of TNFα.
Smad pathway drives osteogenesis, and several studies indicate that
TNFα reduces the phosphorylation of Smads to suppress osteoblast
diﬀerentiation [8,11] whereas others suggest that the stimulation of
TNFα does not change the phosphorylation of Smads in pre-osteoblasts
[32]. These contradictory conclusions may be due to diﬀerent cell types
or diﬀerentiation stages. In our study, the result in multipotent stem
cells supports the observation that TNFα inhibits osteogenesis via de-
creasing BMP2-driven Smad phosphorylation. Moreover, we demon-
strate that pre-treatment of NMP and DMA could fully recover the
TNFα-attenuated Smad signaling.
TNFα activates NF-ĸB signaling which has been widely studied as
key signaling in osteoclasts. Emerging evidence further sheds light on
its roles in regulating osteoblasts [31]. To date, it is known that TNFα
Fig. 4. NMP and DMA eﬀects on Smad and NF-κB signaling pathways. (A) Cells were pre-treated with NMP or DMA, followed by stimulation of indicated con-
centration of TNF-α and rhBMP2 for 48 h. Total cell lysates were extracted and subjected to western blot analysis of the phosphorylation level of Smad1/5/9
complex. pSmad: phosphorylated Smad 1/5/9 complex; tSmad: total Smad 1/5/9/ complex served as a loading control. (B) Cells were starved with 1%FBS medium
for 16 h, and then pre-treated with NMP or DMA, followed by stimulation of indicated concentration of TNF-α and rhBMP2. The amount of phosphorylated p65 and
total p65 in cell lysates were measured at diﬀerent time points (5min and 20min) by western blot analysis. The protein level of p65 served as loading control.
Fig. 5. NMP and DMA eﬀects on ERK signaling pathway. (A) Cells were pre-treated with NMP or DMA and TNF-α, followed by stimulation of indicated concentration
of rhBMP2 for 60min. Cell lysates were isolated. Phosphorylation level of ERK1/2 was examined via western blot analysis. Total ERK served as a loading control. (B)
Cells were ﬁrst pretreated with control solvent (DMSO) or ERK inhibitor, U0126, respectively for 1 h. And then, cells were further treated with NMP or DMA,
followed by stimulation of indicated concentration of TNF-α and rhBMP2 for 6 days. ALP activity was measured by ALP enzymatic activity assay. T: 10 ng/ml TNF-α;
B: 500 ng/ml rhBMP2; TB: TNF-α+rhBMP2. Error bar indicates S.D. from triplicate samples. ***: p < 0.001; ****: p < 0.0001.
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activates NF-ĸB signaling to suppress osteoblastogenesis, thus partially
contributing to reduced bone formation [14,31,32,40,45–48]. Most of
the studies on TNFα have focused on the components at the center of
the classical NF-ĸB pathway, which is p65 (RelA). Upon TNFα stimu-
lation, IKK (IκB kinase) triggers the phosphorylation and subsequent
degradation of IĸB (Inhibitor of ĸB). After the removal of IĸB, p65 can
be phosphorylated by kinases such as IKK, PKAc, MSK-1, and then the
p65:p50 heterodimers are translocated into the nucleus to regulate
transcription of NF-ĸB-target genes [45]. Accordingly, the phosphor-
ylation and nuclear translocation of p65 are the hallmarks of NF-ĸB
signaling activation.
In our study, NMP and DMA did not reduce TNFα-triggered nuclear
translocation of p65 during osteoblastic diﬀerentiation. However, this
result does not exclude the possibility that NMP and DMA might reg-
ulate the transcriptional activity of p65 at the epigenetic level.
Considering that NMP and DMA are low-aﬃnity inhibitors for BRD2,3,4
and BRDT [19,49], their abilities to interfere with activities of bro-
modomain (BD)-containing proteins which regulate the transactivation
activity of p65 appear to be one potential explanation. From this per-
spective, Brd4 seems as an attractive target. Brd4 is associated with the
regulation of the transcriptional activity of p65. The current working
model illustrates that TNFα initiates NF-ĸB signaling, leading to p300-
mediated K310 acetylation on p65. This acetylation further recruits
Brd4, which serves as a coactivator of p65:p50 heterodimers and pro-
motes the binding of CDK9 onto the promoters of NF-ĸB-target genes.
Consequently, CDK9 phosphorylates C-terminal domain (CTD) of RNA
Polymerase II to activate the NF-ĸB-dependent transcription of a subset
of TNFα-responsive genes [50]. Taken together, in the context of TNFα-
inhibited osteogenesis, NMP and DMA might block the activation of NF-
ĸB-dependent genes, such as miR-150-3p [14] or Smurf1/2 [46], by
interfering with the recruitment of Brd4 and CDK9. Therefore, NMP and
DMA appear to facilitate the diﬀerentiation of MSCs to osteoblasts by
blocking the NF-ĸB-mediated TNFα suppression of osteoblast diﬀer-
entiation.
Mitogen-Activating Protein Kinases (MAPKs), particularly ERK1/2,
are signal transduction pathways working parallel with the NF-ĸB
pathway to manifest the inhibitory eﬀect of TNFα in MSCs and osteo-
blasts. Several previous ﬁndings have underlined the importance of
ERK1/2 signaling in TNFα-mediated suppression on osteogenesis
[8,11,40,48]. In line with earlier studies, our data indicate that TNFα
increased the phosphorylation of ERK1/2, especially ERK2. Ad-
ditionally, results from an inhibitor assay conﬁrmed that ERK inhibitor
successfully abrogated the repressive eﬀect of TNFα on the expression
of ALP. Our observation validates the notion that TNFα decreases os-
teoblast diﬀerentiation partially through activating ERK pathway. The
novelty here is that we found that with the pre-treatment of NMP and
DMA, TNFα-triggered phosphorylation of ERK2 was completely
blocked. Altogether, our ﬁndings strongly suggest that NMP and DMA
can counteract the inhibitory eﬀect of TNFα on osteogenesis, at least in
part, via attenuating TNFα-activated ERK signaling. In fact, ERK sig-
naling is well known as primary mediator promoting proliferation [51].
In osteoblasts, studies have shown that the relative strength of ERK
signaling could lead to diﬀerent cell status. For instances, FGF activates
strong ERK signaling but weak AKT signaling to inhibit diﬀerentiation
whereas IGF-1 leads to weak ERK signaling yet robust AKT signaling to
promote diﬀerentiation [52]. Given that diﬀerentiation and prolifera-
tion are mutually exclusive cellular events [53], it is likely that TNFα
inhibits osteogenic diﬀerentiation via facilitating the proliferation of
MSCs while the pre-treatment of NMP and DMA abrogate the pro-
liferation-promoting eﬀect of TNFα, thus allowing BMP2-driven os-
teogenesis to continue.
The metatarsal organ culture, well-established ex vivo system, is a
highly physiological model for studying the eﬀects of exogenous factors
on bone growth and endochondral ossiﬁcation as the growth rate of the
bones mimic that observed in a physiological environment [26]. Here
we demonstrated that the pre-treatment of NMP and DMA completely
abrogated the inhibitory eﬀect of TNFα on BMP2-promoted en-
dochondral ossiﬁcation. Notably, we observed that the treatment of
TNFα alone reduced the length of the pre-existing mineralized matrix,
probably through facilitating osteoclastogenesis and bone resorption
[54]. This observation provides supporting evidence to the notion that
excess TNFα could cause bone resorption resulting in compromised new
bone formation during fracture healing.
5. Conclusion
In the present study, we revealed that NMP and DMA, two FDA-
approved constituents of drug excipient recently characterized as BET
inhibitors, could protect MSCs and osteoprogenitors from the deleter-
ious eﬀect of TNFα during osteogenesis. Mechanistically, NMP and
DMA recover TNFα-inhibited expression of critical osteogenic genes,
including Alp, Runx2, and Osterix. The therapeutic eﬀects of these BET
inhibitors are associated with their abilities to restore TNFα-reduced
Smad signaling and to suppress TNFα-activating ERK pathway. Both
activities appear to be independent of their bromodomain inhibition
since high-aﬃnity bromodomain inhibitors like JQ1 block osteogenesis.
Fig. 6. Therapeutic eﬀects of NMP and DMA on TNFα-compromised endochondral ossiﬁcation of metatarsal bones. Metatarsal bones were extracted from P1 pups of
Sprague Dawley (SD) rats and then cultured with NMP/DMA, TNFα, and rhBMP2 for 14 days. During culturing, images were taken on ﬁrst and the last day for (A) the
measurement of mineralized length in the end. (B) The changes in mineralized length were then calculated. TNF-α: 20 ng/ml; rhBMP2: 500 ng/ml; TB: TNF-
α+rhBMP2; NTB: 20mM NMP+TB; DTB: 20mM DMA+TB. Error bar indicates S.D. from triplicate samples. *: p < 0.05; **: p < 0.01.
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Importantly, the eﬃcacy of NMP and DMA was further validated in an
ex vivo bone growth model where endochondral ossiﬁcation was spared
from TNFα inhibition with the treatment of these small chemicals.
Overall, this study provides promising evidence of using NMP and DMA
as an alternative treatment for inﬂammation-compromised bone
healing in the future.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2019.05.035.
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